$PIII

Short Interest in P3 Health Partners Inc. (NASDAQ:PIII) Rises By 293.3%

P3 Health Partners (NASDAQ:PIII) reported short interest of 283,541 shares as of May 15, up 293.3% from 72,094 on April 30; about 4.8% of shares are sold short, with a days-to-cover ratio near 0.0. The stock fell 26% on Friday to $12.18. UBS and Lake Street set $14 targets; TD Cowen reiterated hold. The company reported Q1 EPS of $0.32 on revenue of $386.39M.

Original reporting
Published May 31, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 31, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Short Interest in P3 Health Partners Inc. (NASDAQ:PIII) Rises By 293.3% — source image
Decision brief

The 30-second read

$PIIINeutralMed
01

Why it matters

A large short-interest increase can amplify price moves via forced covering, especially after an earnings beat. But without new guidance or contract/regulatory catalysts, the move may fade if fundamentals don’t follow through.

02

Market read

Traders may treat this as a positioning-driven volatility setup around a recently reported earnings beat and shifting sell-side targets.

03

What to watch

Days-to-cover is reported as 0.0 despite high average volume, suggesting the metric may be distorted by the article’s data handling; traders should verify the latest cover days and current borrow availability.

Relevance 8/10Novelty 6/10Timing: Positioning/volatility signal immediately after May short-interest update (as of May 15).

Background

The article is a short-interest and post-earnings recap for P3 Health Partners, including analyst target/ratings changes and a 13F institutional buy.

Company-level read

Ticker impact

$PIIINeutralMedium confidence
Context

Article reports P3 Health Partners’ short interest jumped 293.3% in May and highlights recent earnings beat plus analyst target changes.

Expected impact

Elevated volatility; potential short-covering pop if price holds above recent support, but risk remains given heavy short positioning and small market cap.

Evidence & confidence

The piece provides a concrete short-interest datapoint (293.3% rise; 4.8% short) and a recent earnings beat (May 14). However, it lacks forward guidance or new operational catalysts beyond analyst target updates.

Market effects

Healthcare analytics/software names may see read-across from short-interest-driven volatility rather than fundamentals.

Primarily US small/mid-cap sentiment; limited broader regional spillover implied.

Low—single-company microstructure/positioning story.

Counterpoint

Short-interest can rise for reasons unrelated to a near-term squeeze (e.g., persistent fundamental skepticism); the stock’s downtrend may dominate.

Key entities

  • P3 Health Partners Inc.

    Subject of the article; short interest rose 293.3% in May and it reported an EPS beat on May 14.

  • Lido Advisors LLC

    Bought 10,748 shares in Q1 per a 13F filing; owns ~0.15% at quarter-end.

Related articles

$PIIIMedAI 9/10

P3 Health Partners (PIII) Q2 2026 Earnings Call Transcript

P3 Health Partners (PIII) reported Q2 2026 adjusted EBITDA of $54.4 million versus a prior-year loss, on total revenue of $386.4 million (+9% YoY). At-risk membership fell 10% to 105,000. Net income was $15.7 million. The company raised full-year 2026 guidance to adjusted EBITDA of $80 million to $110 million and revenue of $1.5 billion to $1.6 billion.

$PIIIHigh

P3 Health Partners Inc. (PIII): Results of Operations and Financial Condition

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 P3 Health Partners Announces Second Quarter 2026 Results Raises Full-Year 2026 Adjusted EBITDA Guidance Management to Host Conference Call and Webcast August 10, 2026 at 4:30 PM ET HENDERSON, NV—August 10, 2026—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ:

$QTTBMedAI 9/10

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

$EMBJLow

Embraer Stock Sinks After Surprise Credit Upgrade

Embraer's stock fell despite a Moody's credit upgrade to Baa2, likely due to profit-taking and broader market volatility. The upgrade reflects a stronger balance sheet, but investors are cautious about commercial margins and debt. Embraer's order backlog and diversified business offer long-term growth potential.